OOgroup is starting a sale process for its subsidiary Sooft Italia, a pharmaceutical company selling medicines, medical devices and Otc products targeted at the ophthalmic market, Il Sole 24 Ore wrote, adding that Ubs is the mandated advisor for the sale.
Working at the dossier are said to be Healthcare III Fund managed by Italy’s private equity firm Principia sgr; some Italian pharma groups such as Angelini and Mediolanum Farmaceutici; and Luxottica group too, which is said to be interested in entering a new market close to eyewear.
Sooft Italia reached 60.4 million euros in consolidated revenues in 2014 with 12.3 millions in ebitda and a net financial debt of 10.99 millions ( see here an analysis by Leanus, after free registration). This is why an enterprise value in a 5-100 million euros is expected.
